Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of EMZE versus Jardiance 25 mg empagliflozin in healthy Thai volunteers under fasting conditions
TCTR20221003003Phase 1Not yet recruiting
- Sponsor
- Siriraj Institute of Clinical Research
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of empagliflozin (2 arms), sponsored by Siriraj Institute of Clinical Research. Primary endpoint: Plasma drug concentration over 0-48 hours. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
empagliflozin
Beyond the preview
Go deeper on TCTR20221003003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221003003.